Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (231-240 of 251) with videos related to

Pageof 26
Sort By:
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Haematologica|April 4, 2020
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i>-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAli Bazarbachi, Gesine Bug, Frederic Baron, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
British Journal of Haematology|April 4, 2018
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registriesMaría Díez-Campelo, Jose I Lorenzo, Raphael Itzykson, et al.
Blood|September 2, 2020
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemiaLaurène Fenwarth, Xavier Thomas, Stéphane de Botton, et al.
Clinical and Experimental Medicine|August 11, 2022
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseasesVincent Jachiet, Laure Ricard, Pierre Hirsch, et al.
Pageof 26

Showing results (231-240 of 251) with videos related to

Sort By:
Pageof 26
Blood|October 20, 2022
Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trialNaval G Daver, Monique Dail, Jacqueline S Garcia, et al.
Blood Advances|April 25, 2018
Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohortMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
Blood Advances|February 6, 2025
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNetAdriano Venditti, Raffaele Palmieri, Luca Maurillo, et al.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Haematologica|April 4, 2020
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with <i>FLT3</i>-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationAli Bazarbachi, Gesine Bug, Frederic Baron, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 20, 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b TrialMarina Y Konopleva, Monique Dail, Naval G Daver, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 13, 2018
Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective StudyMaximilian Stahl, Michelle DeVeaux, Pau Montesinos, et al.
British Journal of Haematology|April 4, 2018
Azacitidine improves outcome in higher-risk MDS patients with chromosome 7 abnormalities: a retrospective comparison of GESMD and GFM registriesMaría Díez-Campelo, Jose I Lorenzo, Raphael Itzykson, et al.
Blood|September 2, 2020
A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemiaLaurène Fenwarth, Xavier Thomas, Stéphane de Botton, et al.
Clinical and Experimental Medicine|August 11, 2022
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseasesVincent Jachiet, Laure Ricard, Pierre Hirsch, et al.
Pageof 26